Market Cap:
Price Delay ~20min
Interactive 2020
Annual Report

Working with the body to fight cancer, not against it


Allowing lower, better-tolerated doses of chemotherapy and radiotherapy


A disruptive technology to transform the management of cancer


Aiming to move cancer treatments from extending lives to saving lives

Upcoming Events

Our Science

Veyonda is a first-in-class activator of the innate immune system. This is the system that scientists increasingly are beginning to see must be activated if a cancer is to have any chance of being permanently eradicated.

Pipeline and Clinical Trials

Establishing Veyonda as an essential adjunct to radiotherapy in the treatment of prostate cancer and discharging portfolio risk by studying Veyonda in combination with radiotherapy and non-radio therapy treatments.

Noxopharm Announces Major Survival Benefit in Prostate Cancer Patients

Read here further details, including links to the ASX announcement and the conference abstract